Pulmatrix Stock Performance
| PULM Stock | USD 2.46 0.08 3.36% |
The company holds a Beta of -0.79, which implies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Pulmatrix are expected to decrease at a much lower rate. During the bear market, Pulmatrix is likely to outperform the market. At this point, Pulmatrix has a negative expected return of -0.87%. Please make sure to check Pulmatrix's total risk alpha, skewness, as well as the relationship between the Skewness and day median price , to decide if Pulmatrix performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Pulmatrix has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's essential indicators remain very healthy which may send shares a bit higher in March 2026. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return 3.36 | Five Day Return (1.60) | Year To Date Return 8.85 | Ten Year Return (99.50) | All Time Return (99.93) |
Last Split Factor 1:20 | Dividend Date 2019-02-06 | Last Split Date 2022-03-01 |
1 | Pulmatrix Stock Price Crosses Above 50 Day Moving Average Heres What Happened | 11/19/2025 |
2 | Cullgen Reports Positive Results from Phase 1 Study of its Novel Non-Opioid Product Candidate CG001419 for Pain | 12/12/2025 |
3 | Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives | 12/18/2025 |
4 | Behavioral Patterns of PULM and Institutional Flows - Stock Traders Daily | 12/26/2025 |
5 | Acquisition by Siegert Michelle of 9900 shares of Pulmatrix subject to Rule 16b-3 | 01/08/2026 |
6 | Pulmatrix, Inc. Short Interest Update | 01/16/2026 |
7 | Pulmatrix Navigates Strategic Pivot Amid Merger Delays - AD HOC NEWS | 02/10/2026 |
| Begin Period Cash Flow | 20.6 M | |
| Total Cashflows From Investing Activities | -398 K |
Pulmatrix | Build AI portfolio with Pulmatrix Stock |
Pulmatrix Relative Risk vs. Return Landscape
If you would invest 475.00 in Pulmatrix on November 15, 2025 and sell it today you would lose (229.00) from holding Pulmatrix or give up 48.21% of portfolio value over 90 days. Pulmatrix is currently does not generate positive expected returns and assumes 6.1599% risk (volatility on return distribution) over the 90 days horizon. In different words, 55% of stocks are less volatile than Pulmatrix, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Pulmatrix Target Price Odds to finish over Current Price
The tendency of Pulmatrix Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 2.46 | 90 days | 2.46 | about 80.04 |
Based on a normal probability distribution, the odds of Pulmatrix to move above the current price in 90 days from now is about 80.04 (This Pulmatrix probability density function shows the probability of Pulmatrix Stock to fall within a particular range of prices over 90 days) .
Pulmatrix Price Density |
| Price |
Predictive Modules for Pulmatrix
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Pulmatrix. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Pulmatrix Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Pulmatrix is not an exception. The market had few large corrections towards the Pulmatrix's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Pulmatrix, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Pulmatrix within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.78 | |
β | Beta against Dow Jones | -0.79 | |
σ | Overall volatility | 1.02 | |
Ir | Information ratio | -0.15 |
Pulmatrix Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Pulmatrix for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Pulmatrix can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Pulmatrix generated a negative expected return over the last 90 days | |
| Pulmatrix has high historical volatility and very poor performance | |
| Pulmatrix has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 7.81 M. Net Loss for the year was (9.56 M) with loss before overhead, payroll, taxes, and interest of (7.16 M). | |
| Pulmatrix currently holds about 42.91 M in cash with (10.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.67, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Pulmatrix has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Pulmatrix Navigates Strategic Pivot Amid Merger Delays - AD HOC NEWS |
Pulmatrix Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Pulmatrix Stock often depends not only on the future outlook of the current and potential Pulmatrix's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Pulmatrix's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 3.7 M | |
| Cash And Short Term Investments | 9.5 M |
Pulmatrix Fundamentals Growth
Pulmatrix Stock prices reflect investors' perceptions of the future prospects and financial health of Pulmatrix, and Pulmatrix fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pulmatrix Stock performance.
| Return On Equity | -0.79 | ||||
| Return On Asset | -0.47 | ||||
| Current Valuation | (645.95 K) | ||||
| Shares Outstanding | 3.65 M | ||||
| Price To Earning | (1.30) X | ||||
| Price To Book | 1.88 X | ||||
| Price To Sales | 2,897 X | ||||
| Revenue | 7.81 M | ||||
| Gross Profit | (7.16 M) | ||||
| EBITDA | (7.04 M) | ||||
| Net Income | (9.56 M) | ||||
| Cash And Equivalents | 42.91 M | ||||
| Cash Per Share | 12.67 X | ||||
| Total Debt | 996 K | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 8.19 X | ||||
| Book Value Per Share | 1.30 X | ||||
| Cash Flow From Operations | (10.72 M) | ||||
| Earnings Per Share | (1.71) X | ||||
| Market Capitalization | 8.69 M | ||||
| Total Asset | 9.94 M | ||||
| Retained Earnings | (297.16 M) | ||||
| Working Capital | 8.99 M | ||||
| Current Asset | 8.34 M | ||||
| Current Liabilities | 4.11 M | ||||
About Pulmatrix Performance
By examining Pulmatrix's fundamental ratios, stakeholders can obtain critical insights into Pulmatrix's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Pulmatrix is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 2.76 | 2.45 | |
| Return On Tangible Assets | (0.87) | (0.91) | |
| Return On Capital Employed | (0.97) | (1.02) | |
| Return On Assets | (0.87) | (0.91) | |
| Return On Equity | (0.96) | (1.01) |
Things to note about Pulmatrix performance evaluation
Checking the ongoing alerts about Pulmatrix for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Pulmatrix help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pulmatrix generated a negative expected return over the last 90 days | |
| Pulmatrix has high historical volatility and very poor performance | |
| Pulmatrix has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 7.81 M. Net Loss for the year was (9.56 M) with loss before overhead, payroll, taxes, and interest of (7.16 M). | |
| Pulmatrix currently holds about 42.91 M in cash with (10.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.67, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Pulmatrix has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Pulmatrix Navigates Strategic Pivot Amid Merger Delays - AD HOC NEWS |
- Analyzing Pulmatrix's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pulmatrix's stock is overvalued or undervalued compared to its peers.
- Examining Pulmatrix's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pulmatrix's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pulmatrix's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pulmatrix's stock. These opinions can provide insight into Pulmatrix's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pulmatrix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Will Pharmaceuticals sector continue expanding? Could Pulmatrix diversify its offerings? Factors like these will boost the valuation of Pulmatrix. Anticipated expansion of Pulmatrix directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Pulmatrix data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.71) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
The market value of Pulmatrix is measured differently than its book value, which is the value of Pulmatrix that is recorded on the company's balance sheet. Investors also form their own opinion of Pulmatrix's value that differs from its market value or its book value, called intrinsic value, which is Pulmatrix's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Pulmatrix's market value can be influenced by many factors that don't directly affect Pulmatrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Pulmatrix's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Pulmatrix should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Pulmatrix's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.